SCANCELL HOLDINGS PLC: Interim Results for the six months ended 31 October 2023

Life Sciences

Scancell’s Phase 2 SCOPE trial for advanced melanoma impressed – with Initial data from 11 patients showing an 82% objective response rate (ORR) to treatment, handily surpassing the 50% ORR seen with competing drugs.

Author:
Date: January 31, 2024

Download in PDF

Strong clinical progress in the SCOPE trial with 85% ORR reported from the first 13 patients with
unresectable melanoma
Post-period end capital raise of £11.9m to support important clinical milestones in 2024
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces its interim results for the six months ended 31 October 2023 and provides a business update on progress achieved to date.

Highlights (including post period):

SCIB1 (SCOPE trial)

  • SCIB1, an oncology vaccine, reported positive data from the first stage of its Phase 2 SCOPE trial for
    advanced melanoma.
  • SCIB1 in combination with checkpoint inhibitors (CPIs) showed an 85% objective response rate (ORR)
    to treatment in 13 patients, exceeding the target of 70% ORR and accompanied by meaningful tumour volume reduction. One patient achieved a complete response following treatment.
  • In the real word setting in patients receiving doublet standard of care CPI therapy alone, the ORR is
    50% with a progression free survival of 11.5 months.
  • Recruitment in the second stage is expected to be complete in Q1 2024 with highly anticipated data
    available in Q3 2024.
  • The addition of iSCIB1+ to the SCOPE trial has been approved by the MHRA. Recruitment in this third cohort is expected to start in Q1 2024 with early data available in Q3 2024. iSCIB1+ includes additional melanoma-specific epitopes so it has the potential to be even more effective in a broader patient population.
  • A clear development pathway for registration and approval of SCIB1/ iSCIB1+ in the medium term for
    advanced melanoma has been mapped out.
  • This represents a potential $1.5 billion per annum market and we anticipate significant interest from
    potential partners.

Modi-1 (ModiFY trial)

  • In July 2023, the ModiFY trial moved into the expansion cohorts, following approval by the safety
    review committee.
  • Early data from patients receiving Modi-1 as a monotherapy showed good T cell responses, safety
    and tolerability, with no dose limiting toxicities observed in dose escalation cohorts. Similar to SCIB1
    monotherapy in metastatic disease, one patient achieved a partial response and 60% of patients
    showed stable disease in response to Modi-1 monotherapy.
  • Modi-1 to be assessed in renal cell carcinoma in combination with double CPI therapy in the ModiFY
    study pending protocol amendment by the MHRA.
  • Early clinical data from patients treated with Modi-1 plus CPIs is anticipated in 2024.
    Antibodies:
  • Development of SC129, out licensed to Genmab, continues on track towards potential clinical
    development.
  • GlyMab® and AvidiMab® platforms provide potential out licensing opportunities with active discussions ongoing with pharmaceutical and biotech companies.
    Corporate:
  • Sath Nirmalananthan appointed as Chief Financial Officer
  • Dr Mandeep Sehmi appointed as Head of Business Development
    Financial:
  • In December 2023, the Company raised gross proceeds of £11.9 million in aggregate (before
    expenses) through the capital raise with significant participation from both existing and new healthcare specialist investors.
  • Group cash balance at 31 October 2023 was £13.1 million (April 2023: £19.9 million) with cash funding through to important clinical milestones on clinical assets.

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “The Scancell team continues to
produce highly-significant data across its pipeline of cancer vaccines and we have made strong progress in all parts of the business in the first six months of the year. Most notably, we were pleased to announce exceptional data from the first stage of the SCOPE trial with SCIB1 showing an 85% ORR to treatment in 13 patients, exceeding 70% ORR expectations. With important clinical milestones expected this year, including further data from both the SCOPE and ModiFY trials, and with the recently secured funding in place, the company’s prospects in 2024 are exciting.”
Professor Lindy Durrant, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will also host a live webcast and Q&A session for analysts and investors today at 14:00 GMT. If you would like to join the webcast, please follow this link: https://www.lsegissuerservices.com/spark/ScancellHoldings/events/f581274b-146c-4a89-af15-
05bcae874775

Share this post
Disclaimer

Disclaimers and Important Notes

This information (“Information”) is for private use, for information and discussion purposes only. The Information is not and does not constitute, and under no circumstances should it be considered as or intended to form part of any offer, recommendation, invitation or solicitation to subscribe to or to enter into any transaction, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction and should not be viewed as such. The Information does not intend to express any opinion on the merits of buying, selling or holding a particular investment product or a class of investment products.

This is not investment research and it is for information only. It should not be relied upon as financial advice. It has not been prepared in accordance with legal requirements designed to promote the independence of research, it is not intended to constitute independent, impartial or objective research analysis or recommendations and should not be treated or relied on as such. The provision of this Information is not regulated by any regulatory authority, including the Monetary Authority of Singapore, or under any regulation, including the Financial Advisors Act of Singapore and the Securities and Futures of Singapore. Notwithstanding this, the Information is not presented with the intention of inducing a person to buy, sell or hold a particular investment product or a class of investment products. Any terms, conditions and opinions contained herein may have been obtained from various sources and neither “Vulpes” nor any of its related companies or affiliates nor any of their respective directors or employees make any warranty, expressed or implied, as to its accuracy or completeness and thus assume no responsibility for it. 

The Information may be subject to further revision, verification and updating and Vulpes undertakes no responsibility thereof. All figures and amounts stated are for illustration purposes only and shall not bind Vulpes. Vulpes does not act as an adviser and is not in the business of providing financial advice. Vulpes assumes no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any arrangement or entrance into any transaction in reliance on the information contained herein. This Information is generic and is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this Information. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed in the Information. The Information may contain forward looking statements which are often but not always identified by the use of words such as “anticipate”, “believe”, “estimate”, “intend”, “plan”, “expect”, “forecast”, “predict” and “project” and statements that an event or result “may”, “will”, “can”, “should”, “could” or “might” occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward-looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. Vulpes expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

All information, estimates, forecasts and opinions included in this document may be subject to change without notice. Changes in market conditions or in any assumptions may have a material impact on any estimates or opinion stated. In any event, past performance is no guarantee of future results, and future results may not meet expectations due to a variety of economic, market and other factors. Any information relating to past performance, or any future forecast based on past performance or other assumptions, is not necessarily a reliable indicator of future results. If the Information has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of the Information, which may arise as a result of electronic transmission. The Information is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

Country Specific Notices

United Kingdom: This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with or act as an inducement to enter into any contract or commitment whatsoever.

This document is only addressed to and directed at persons resident in the United Kingdom and who are “Qualified Investors” within the meaning of article 2(e) of The Prospectus Regulation (EU) 2017/1129 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) (“Qualified Investors”). In addition, in the United Kingdom, this document has not been approved by an authorised person pursuant to section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and, as such, this document is being distributed only to, and is directed only at, qualified investors (i) who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2005 (the “Order”) or are Qualified Investors falling within article 49 of the Order, and (ii) to whom the information may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The information in this document must not be acted on or relied on in the United Kingdom, by persons who are not relevant persons. This document must not be acted on or relied on in the United Kingdom, by persons who are not both Relevant Persons and Qualified Investors.

United States of America: This document is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not intended to create legal relations on the basis of information provided herein.
Singapore: If this document is distributed in Singapore, it is made available through general information circulation only it is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not intended to create legal relations on the basis of information provided herein. The contents of the Materials have not been reviewed by in the Monetary Authority of Singapore.

South Africa: This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. The views in this publication are those of the author(s) and are subject to change and “Vulpes” has no obligation to update its opinions or the information in this publication. If this publication contains recommendations, those recommendations reflect solely and exclusively those of the author(s) and such opinions were prepared independently of any other interests. This publication does not constitute personal investment advice.

Read more insights

Subscribe to our newsletter to receive our latest news and updates!